Archives

Categories

About

Subscribe to this blog's feed
Add me to your TypePad People list

Copyright notice

  • TNFMedicine.com © 2007 Edward Lewis Tobinick MD, A Medical Corporation. All Rights Reserved.

Disclaimer

  • The views expressed in this blog are my personal thoughts and opinions. I maintain this blog for my own use, to categorize important medical information for myself as it develops. Posts are for informational and educational purposes only. This blog does not constitute medical advice, and none of its posts should be interpreted or relied on as such. This blog does not constitute a solicitation for business. No claims, promises, or guarantees about the accuracy of the information herein are made. Sending me an e-mail does not create a physician-patient relationship. Many of the posts herein contain abstracts and citations which are publically available at www.pubmed.gov, the online medical article database from the National Library of Medicine(which has no affiliation with this site). Many of the posts contain information regarding off-label uses of biologic TNF antagonists. This website should not be interpreted to imply or explicitly make or propose any treatment recommendations. The off-label uses discussed on this website are uses which are, by definition, not FDA-approved. Therefore the safety and efficacy of these uses have not yet been confirmed nor endorsed by the FDA, and no recommendation regarding the use of these reported methods is inferred or implied by their inclusion on this website. Biologic TNF-anatagonists, such as etanercept, infliximab, and adalimumab can have serious adverse effects, such as death, infection, cytopenias, and may be associated with an increased risk of lymphoma, demyelinating disease, eye inflammation, and congestive heart failure. Medical consultation prior to their use is mandatory.

Patent Notice

  • The following U.S. patents have been issued to Edward Tobinick MD concerning selected uses of certain biologic TNF antagonists and other cytokine antagonists for selected neurological and related indications in humans: 6,015,557; 6,177,077; 6,379,666; 6,419,934; 6,419,944; 6,423,321; 6,471,961; 6,428,787; 6,537,549; 6,982,089. Also Australian patent 758,523. Additional U.S. and foreign patents are pending.

« Human immunodeficiency virus type-1 protein Tat induces tumor necrosis factor-alpha-mediated neurotoxicity. | Main | New Anti-TNF Approach for Alzheimer's Disease - New Patent Issues »

May 08, 2007

Association of Tumor Necrosis Factor Polymorphisms with Guillain-Barré Syndrome.

Title Association of Tumor Necrosis Factor Polymorphisms with Guillain-Barré Syndrome.
Author(s) Zhang J, Dong H, Li B, Li CY, Guo L
Institution Second Hospital of Hebei Medical University, Shijiazhuang, PR China.
Source Eur Neurol 2007 May 4; 58(1) :21-25.
Abstract It has been reported that the tumor necrosis factor (TNF)alpha promoter polymorphism is associated with autoimmune disease and inflammatory disease. It has also been claimed that this polymorphism may affect TNFalpha expression. We investigated the TNFalpha -308 polymorphism and TNFalpha levels in 79 unrelated Chinese patients with Guillain-Barré syndrome (GBS) and 78 healthy controls using PCR-RFLP and ELISA assay. Patients with GBS were divided into 2 subgroups, acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and acute motor axonal neuropathy (AMAN), based on electrophysiological information. We found that the TNFalpha2 allele was associated with increased risk of GBS (OR = 1.876, 95% CI = 1.144-3.075, p = 0.008), particularly for AMAN, the main subtype (OR = 2.914, 95% CI = 1.412-6.015, p = 0.004), but there was no association between TNFalpha polymorphism and AIDP. We also found that carriers of the TNFalpha2 allele had significantly higher TNFalpha2 levels than TNFalpha1 homozygotes (p < 0.05). These data indicate that TNFalpha promoter polymorphism is responsible for susceptibility to GBS, especially to AMAN. The TNFalpha2 allele is associated with higher levels of TNFalpha. Copyright (c) 2007 S. Karger AG, Basel.
Language ENG
Pub Type(s) JOURNAL ARTICLE
PubMed ID 17483581

Posted at 07:12 AM in TNF in General Medicine |

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d83421064353ef00d8350135cd53ef

Listed below are links to weblogs that reference Association of Tumor Necrosis Factor Polymorphisms with Guillain-Barré Syndrome.:

Comments

The comments to this entry are closed.